Артериальная гипертензия

Расширенный поиск

Менопаузальный метаболический синдром (современное состояние проблемы)

Полный текст:

Об авторах

Д. А. Аничков

Н. А. Шостак

Список литературы

1. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001: 285: 2486-97.

2. European guidelines on cardiovascular diseases-prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10: S1-10.

3. Ford E.S., Giles W.H., Dietz W.H. Prevalence if the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002: 287: 356-9.

4. Miller A.M., Wilbur J., Chandler P.J., Sorokin O. Cardiovascular disease risk factors and menopausal status in midlife women from the former Soviet Union. Women Health 2003; 38: 19-36.

5. Spencer C.P., Godsland I.F., Stevenson J.C. Is there a menopausal metabolic syndrome? Gynecol Endocrinol, 1997; 11: 341-55.

6. Carr M.C. The emergence o/the metabolic syndrome with menopause. J Clin Endocrinol Metah 2003; 88: 2404-11.

7. Faria A.N., Riheiro Filho F.F., Gouveia Ferreira S.R., Zanella M.T. Impact of visceral fat on blood pressure and insulin Sensitively in hypertensive obese women. Obes Res 2002: 10: 1203-6.

8. Hrochu M., Starling R.D., Tchernof A. et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab 2000; 85: 2378-84.

9. Rendell M., Hulthen U.L., Tornquist С. et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early post-menopausal women. J Clin Endocrinol Melab 2001; 80: 744-9.

10. Heruandez-Ono A., Monter-Carreola G., Zamora-Gonzalez J. et al. Association of visceral fat with coronary risk factors in population-based sample of postmenopausal women. Int J obes Relat Metab Disord 2001: 26: 33-9.

11. Van Pelt R.E., Evans E.M., Schechtman K.B. et al. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Oges Relat Metab Disord 2001: 25: 1183-8.

12. Lovergrove J.A., Sitva K.D.R.R., Wright J.W., Williams C.M. Adiposity, insulin and lipid metabolism in post-menopausal women. Int J Obes Relat Metab Disord 2002; 26: 475-86.

13. Walton С., Godsland I.F., Proudler A.J. et al. The effects oj the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur/J Clin Invest 1993: 23: 466-73.

14. Nilsson P.M., Lind L., Pollare T. et al. Differences in insulin sensitivity and risk, marker due to gender and age in hypertensives. J Hum Hypertens 2000; 14: 51-6.

15. Kim H.S., Abbasi F., Lamendola С. et al. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 2001; 74; 592-5.

16. Feldstein C.A., Akopian M., Renauld A. et al. Insulin resistance antihypertension in postmenopausal women. J Hum Hypertens 2002; 16 (Suppl. 1): S145-50.

17. Toth M.J., Sites C.K., Eltabbakh G.H., Pochiman E.T. Effect of menopausal status on insulin-Stimulated glucose disposal: comparison of middle-aged pre-menopausal and early postmenopausal women. Diabetes Care 2000; 23: 801-6.

18. Staessen J., Bulpit C.J., Fagard R. et al. The influence of menopause on blood pressure. J Hum Hypertens 1989: 3: 427-33.

19. Staessen J., Ginocchio C., Thijs L., Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997; 11: 507-14.

20. Wassertheil-Smoller S., Anderson G., Psaty B.M. et al. Hypertension and its treatment in postmenopausal women: baseline data from Women's Health initiative. Hypertension 2000; 36: 780-9.

21. Schillaci G., Verdecchia P., Borgioni С. et al. Early cardiac changes after menopause. Hypertension 1998: 32: 764-9.

22. Sherwood A., Thurston R., Steffen P. et al. Blunted nighttime blood pressure dipping in postmenopausal women. Am J Hypertens 2001; 14: 749-54.

23. Rosental T., Oparil S. Hypertension in women. J Hum Hypertens 2000; 14: 691-704.

24. Kolchen J.M., Kolchen Т.А. Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 2003: 5: 505-12.

25. Nickenig G., Baumer A.T., Grohe С. el al. Estrogen modulates ATI receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-201.

26. Vilecco A.S., de Aloyso D., Radi D. et al. Plasma catecholamines in pre- and postmenopausal women with mild to moderate essential hypertension. J Hum Hypertens 1997; 11: 152-62.

27. Vongpatanasin W., Tuncel M., Mansour Y. et al. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001; 103: 2903-8.

28. Barhagallo M., Dominguez L.J., I.icata G., Resnick I.M. Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes. Hypertension 1999: 34: 902-6.

29. Tsuda K., Kinoshita Y., Kimura К. et al. Electron paramagnetic resonance investigation on modulatory effect of 17h-estradiol on membrane fluidity of erythrocytes in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1306-12.

30. Anichov D.A., Maksina A.G., Shostak N.A. Relations of erythrocyte membrane properties to components of metabolic syndrome in women. Med Sci Monit. In press.

31. Сметник В.И., Шестакова И.Г. Менопауза и сердечно-сосудистая система. Тер. арх. 1999: 10: 61-5.

32. LaRosa J.С. Evidence-based management of dyslipidemias in women. Curr Atheroscler Rep 2003: 5: 379-85.

33. Effects of estrogen or estrogen/progestin regimens on heart diseases risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995: 273: 199-208.

34. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.

35. Sowers J.R. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998: 158: 617-21.

36. Bolego C., Poli A., Paoletti R. Cardiovascular risk in diabetic women. Curr Atheroscler Rep 2003: 5: 79-81.

37. Howard B.V., Cowan L.D., Go О. et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998: 21: 1258-65.

38. Barrett-Connor E.L., Cohn B., Wingard D. et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 1991; 265: 627-31.

39. Aronson D., Rayfield E.J. How hyperlycemia atherosclerosis: molecular mechanisms. Cardiovasc Diabelol 2002; 1: 1.

40. Wilson P.W., Kannell W.B., Silbershatz H., D'Agostino R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999: 159:1104-9.

41. Chan J.C.N., Cheung J.C.K., Stehouwer C.D.A. et al. The central roles of odbesity-assicialed dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modeling, but J Obes Relat Metab Disord 2002; 20: 994-1008.

42. Das U.N. Metabolic syndrome X: an inflammatory condition? Curr Hypertens Rep 2004: 6: 66-73.

43. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.

44. Frochlich M., Imhof A., Berg G. et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.

45. Festa A., D'Agostino R., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000: 102: 42-7.

46. Chae C.U., Lee R.T., Rifal N., Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 2001: 38: 399-403.

47. Ahramson J.L., Weintrauh W.S., Vaccarino V. Associatiou between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39: 197-202.

48. Lin Y., Rajala M.W., Berger J.P. el al. Hyperglycemia-induced production of acute phase readouts in adipose tissue. J Biol Chan 2001; 270: 42077-83.

49. Kern P.A., Di Georgio G.B., Lu T. et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-a expression. Diabetes 2003: 52: 1779-85.

50. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90-119.

51. Han T.S., Sattar N., Williams R. et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care: 25: 2010-21.

52. Ridker P.M., Rifai N., Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.

53. Engeti S., Feldpausch M., Gorzelniak R. et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-7.

54. Esposito R., Ponlillo A., Di Pato С. et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003: 289: 1799-804.

55. Sciacqua A., Candigliota M., Ceravolo R. et al. Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003: 20: 1673-8.

56. Mosca L., Collins P., Herrington D.M. et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104; 499-503.

57. Luyer M.D.P., Khosla S., Owen W.G. Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markets of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001; 80: 3629-34.

58. Koh K.K., Schenke W.H., Waclawiw M.A. et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in post-menopausal women. Circulation 2002; 105: 1531-3.

59. Mostaghel E., Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev 2003: 11:4-12.

60. Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Клин. фармакол. тер. 2000; 2: 5-30.

61. European Society of Hypertension-European Society of Cardioiogy guidelines for the management of arterial hypertension. J Hypertens 2003: 21: 1011-53.

62. Fisman E.Z., Tenenbaum A., Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002; 4: 464-70.

63. Haenni A., Ltlhell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999. 17 (Suppl. 3): S29-35.

64. Подзолков B.И., Брагина А.Е., Маколкин В.И. Патогенетическая роль моксонидина при лечении артериальной гипертензии у женщин в перименопаузе. Кардиология 2002; 11: 32-5.

65. Аничков Д.А., Шосшак Н.А. Эффективность моксонидина у женщин с артериальной гипертензией в рамках метаболическою синдрома при исходно высокой частоте сердечных сокращений. Кардиология 2002; 11: 40-3.

Для цитирования:

Аничков Д.А., Шостак Н.А. Менопаузальный метаболический синдром (современное состояние проблемы). Артериальная гипертензия. 2004;10(3):143-146.

For citation:

Anichkov D.A., Shostak N.A. Menopausal metabolic syndrome: state-of-the-art. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2004;10(3):143-146. (In Russ.)

Просмотров: 269

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)